The grass-roots market is about to explode, and a group of pharmaceutical companies are recruiting pharmaceutical representatives.

Pharmaceutical Network Industry Dynamics Recently, at the same time that Takeda Pharmaceuticals has eliminated sales staff, a number of pharmaceutical companies are recruiting pharmaceutical representatives, including cancer immunotherapy giant Mercado, global in vitro diagnostics leader Roche Diagnostics, as well as the domestic pharmaceutical industry leader Shi pharmaceutical group and other well-known pharmaceutical companies.
industry believes that as the reshuffle intensifies, medical representatives will return to the essence of academic promotion.
many pharmaceutical companies are planning to sink their business estomino to primary health care or four-tier five-line cities, to form grass-roots sales forces and compete for hundreds of billions of grass-roots markets, which is a new opportunity for pharmaceutical representatives.
Mershadong is understood that The recent murray is for the tumor PD-1 therapy Keytruda this product recruitment of a number of pharmaceutical information consultants, responsible for the region in Chengdu (urban areas and Jane Yang), Chongqing (urban areas and Wanzhou, Yongzhou and other surrounding), Deyang, Guangyuan, Panzhihua and Xichang, Zigong, Neijiang and other places.
data show that Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, activating T lymphocytes that may affect tumor cells and healthy cells.
keytruda is a leader in PD-(L) 1 tumor immunotherapy, with more than 20 therapeutic indications approved, with global sales reaching $11.1 billion in 2019, up 58 percent from the previous year.
in The country, Keytruda has been approved for the treatment of esophageal squamous cell carcinoma (ESCC).
With this new approval, Keytruda is now approved in China for five indications for three different types of cancer, including first-line treatment (single drug therapy and combined chemotherapy) for patients with advanced non-small cell lung cancer (NSCLC) and second-line treatment as advanced melanoma.
Roche Diagnostics Roche Diagnostics is recruiting clinical extension specialists for products such as heart markers, severe markers, tumor markers, and is responsible for Zhengzhou and Taiyuan (two positions) regions.
requireacademic influence, control ability of large customers and other conditions.
data show that Roche Diagnostics is committed to developing and delivering innovative, cost-effective, timely and reliable diagnostic systems and solutions, from early detection, prevention to diagnosis and surveillance.
August 2000, Roche Diagnostic Products (Shanghai) Co., Ltd. was established as a wholly foreign-owned company in Shanghai's Outer Takahashi Free Trade Zone to carry out Chinese mainland business.
has more than 2,000 employees in more than 70 cities across the country. Headquartered in Shanghai,
has branches in Beijing, Guangzhou, Nanjing, Hangzhou and Jinan.
Jimin Trusted Jimin Trust is recruiting academic representatives for nephroline products, responsible for the core market in Chongqing.
requires more than one year's experience in clinical promotion of medicine, as well as excellent academic promotion ability, department meeting and academic conference organization ability and other conditions.
it is understood that Jimin credibility in the field of kidney disease, respiratory, pain and cardiovascular treatment has achieved fruitful results, in microspheres, lipids and inhalers and other special preparations have a domestic leading advantage.
the company is currently working hard with technical barriers to the difficult type of generic drugs, fine characteristics of innovative Chinese medicine, forward-looking layout of core technology and innovative drugs, the formation of a modern, intelligent, efficient research and development system and differentiated competitive layout.
Stone Pharmaceutical Group Ishiguro Group for ke aili (albumin yew alcohol) anti-tumor division recruitment representative / high generation / academic director, responsible for Shanghai Chest Hospital, Shanghai Jiaotong University affiliated Renji Hospital area.
February 2018, Stone Pharmaceutical Group's Ackley was approved for listing, according to public data, the first three quarters of 2019, Stone Pharmaceutical Group Keaili sales of 1.1 billion yuan. on May 27,
, Ishiguro Group reported first-quarter 2020 results, which reported operating income of RMB6.13 billion in the first quarter, up 11.5% YoY, and net profit of RMB1.16 billion in the first quarter, up 21.8% YoY.
among them, the anti-tumor drugs Keaili (injection with yew olthanin binding type) and ZinYuli (polyethylgrererererereregenic recombinant human granulocyte stimulation agent injection), polymetry (hydrochloric acid polyrous star lipid injection) recorded sales revenue of 1.552 billion yuan, an increase of 53.7% yoy.
, the company's sales revenue increased by 114.0 percent.
.